Literature DB >> 7858264

Downregulation of proinflammatory cytokine release in whole blood from septic patients.

W Ertel1, J P Kremer, J Kenney, U Steckholzer, D Jarrar, O Trentz, F W Schildberg.   

Abstract

Using animal models or healthy volunteers, injection of lipopolysaccharide (LPS) or bacteria causes activation of macrophages with excessive synthesis and secretion of proinflammatory cytokines. Although these models mimic the effects of LPS in the host, they may represent more of an experimental expression of endotoxemia than natural infection itself. Therefore, as an ex vivo model of sepsis, whole blood from 15 patients with severe sepsis and 20 control patients without infection was stimulated with LPS to study the kinetics of mRNA expression and release of proinflammatory cytokines, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL-6. Stimulation of whole blood with 1 microgram/mL LPS resulted in a maximum increase of cytokine secretion in the control group, while a marked (P < .01) depression of TNF-alpha, IL-1 beta, and IL-6 release was observed in the septic group, which persisted up to 10 days after study enrollment. While IL-1 beta mRNA expression was similar in peripheral blood mononuclear cells (PBMCs) harvested from LPS-stimulated whole blood in septic and control patients, the half-life and consequently the expression of TNF-alpha and IL-6 mRNA were strongly reduced in the septic group. These data indicate a downregulatory mechanism of cytokine release in whole blood from patients with severe sepsis that occurs on different levels. Although excessive secretion of proinflammatory cytokines has been considered deleterious for the host, the reduced capacity of PBMCs in whole blood from septic patients to synthesize and secrete proinflammatory cytokines to an inflammatory stimulus may result in immunodeficiency, because these cytokines in low concentrations are involved in the upregulation of essential cellular and humoral immune functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7858264

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  107 in total

1.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

2.  Is monocyte HLA-DR expression predictive for clinical outcome in sepsis?

Authors:  Andreas Spittler; Erich Roth
Journal:  Intensive Care Med       Date:  2003-08       Impact factor: 17.440

3.  [Clinical course and prognostic significance of immunological and functional parameters after severe trauma].

Authors:  S Lendemans; E Kreuzfelder; C Waydhas; D Nast-Kolb; S Flohé
Journal:  Unfallchirurg       Date:  2004-03       Impact factor: 1.000

Review 4.  Advances in the management of sepsis and the understanding of key immunologic defects.

Authors:  Lee P Skrupky; Paul W Kerby; Richard S Hotchkiss
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

Review 5.  Sepsis: a clinical update.

Authors:  Corey E Ventetuolo; Mitchell M Levy
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-07       Impact factor: 8.237

6.  Mechanisms of sepsis and insights from clinical trials.

Authors:  Nitin Seam; Anthony F Suffredini
Journal:  Drug Discov Today Dis Mech       Date:  2007

7.  High interleukin 12 and low interleukin 10 production after in vitro stimulation detected in sepsis survivors.

Authors:  Spaska A Stanilova; Zhivko T Karakolev; Gospodin S Dimov; Zlatka G Dobreva; Lyuba D Miteva; Emil S Slavov; Chavdar S Stefanov; Noyko S Stanilov
Journal:  Intensive Care Med       Date:  2005-02-18       Impact factor: 17.440

8.  Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism.

Authors:  Melanie J Scott; Shubing Liu; Richard A Shapiro; Yoram Vodovotz; Timothy R Billiar
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 9.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

10.  Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS.

Authors:  Jun Muto; Kenshi Yamasaki; Kristen R Taylor; Richard L Gallo
Journal:  Mol Immunol       Date:  2009-09-24       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.